FDA Rejects Amgen Hormonal-Imbalance Treatment

August 25, 2016 3:22 PM

4 0

Etelcalcetide, or Parsabiv, is for treatment of secondary hyperparathyroidism in patients with chronic kidney disease

Amgen Inc. AMGN -0.09 % said Wednesday that government regulators have rejected its new drug application for its therapy for a hormonal imbalance common in patients on dialysis.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page